The patient is intradermally injected with 0.5-3 mg of the HLA-A*2402-restricted, 9-mer modified WT1 peptide (p235-243:CYTWNQMNL) emulsified with Montanide ISA51 adjuvant. The WT1 vaccination is sched

2 trials

Sponsors

Osaka university graduate school of medicine, Osaka University Graduate School of Medicine

Conditions

Pediatric soft tissue malignancy and neuroblastomapediatric malignant tumor, hematological malignancy

Phase 1

WT1 peptide vaccination for pediatric patients: phase I/II study.

Active, not recruitingJPRN-UMIN000013252

Osaka University Graduate School of Medicinepediatric malignant tumor, hematological malignancy

Start: 2006-04-24Target: 20Updated: 2026-06-29

Phase 2

Immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Active, not recruitingJPRN-UMIN000013251

Osaka university graduate school of medicinePediatric soft tissue malignancy and neuroblastoma

Start: 2008-08-20Target: 22Updated: 2026-06-29